Smith College

- Specific antibody responses to RBD and neutralizing antibodies to live SARS-CoV-2 and pseudovirus
- Specific T-cell responses
- Adverse reactions by time


Results - Study on immunogenicity and safety of Ad5-vectored COVID-19 vaccine in larger population

Zhu FC, Guan XH, Li YH, Huang JY, Jiang T, Hou LH, Li JX, Yang BF, Wang L, Wang WJ, Wu SP, Wang Z, Wu XH, Xu JJ, Zhang Z, Jia SY, Wang BS, Hu Y, Liu JJ, Zhang J, Qian XA, Li Q, Pan HX, Jiang HD, Deng P, Gou JB, Wang XW, Wang XH, Chen W. Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet. doi: 10.1016/S0140-6736(20)31605-6.

https://reader.elsevier.com/reader/sd/pii/S0140673620316056?token=97B865EF00C0E8CED18EB943DA8BC3625887370F6AD86C661591D78080B9D0ADF7A2E0703365A9D821BE21A8F2E5D70E

Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial

Specific T-cell responses - Study on immunogenicity and safety of Ad5-vectored COVID-19 vaccine in larger population

Adverse reactions by time - Study on immunogenicity and safety of Ad5-vectored COVID-19 vaccine in larger population

Specific antibody responses to RBD and neutralizing antibodies to live SARS-CoV-2 and pseudovirus - Study on immunogenicity and safety of Ad5-vectored COVID-19 vaccine in larger population

Learn Before

Related